Search terms included combinations of GLP-1 receptor agonist, semaglutide, liraglutide, tirzepatide, cutaneous side effects, dermatology, hidradenitis, psoriasis, bullous pemphigoid, facial aging, and plastic surgery. Of 260 articles initially identified, 155 were included on the basis of predefined eligibility criteria prioritizing randomized controlled trials, observational studies, systematic reviews, regulatory reports, and clinically relevant case series in adult populations
Better Cholesterol Profiles: These medications can improve lipid profiles, leading to lower levels of bad cholesterol and triglycerides
Exendin-4-induced changes in [Ca 2+ ] i of the GC soma are shown in three CCD images (Fig
GLP-2 acts through GLP-2R, a highly specific GPCR located in the gastrointestinal tract, pancreas, and central nervous system (6063)
For researchers who find themselves frequently missing doses, consider whether your timing strategy needs adjustment
Studies in patients with type 2 diabetes and obesity have demonstrated that the use of SGLT2 inhibitors, particularly empagliflozin, not only increases overall cancer risk but also significantly elevates the risk of bladder cancer [10, 108]
